Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center

References

• O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11):3186–3191.
   PubMed Web of Science ®Google Scholar
• Mejstrikova E, Hrusak O, Borowitz MJ, et al. Cd19-negative relapse of pediatric b-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017;7(12):659. doi:10.1038/s41408-017-0023-x
   PubMed Web of Science ®Google Scholar
• DeFilipp Z, Advani AS, Bachanova V, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: Updated 2019 evidence-based review from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019;25(11):2113–2123. doi:10.1016/j.bbmt.2019.08.014
   PubMed Web of Science ®Google Scholar
• Wu H, Medeiros LJ, Young KH. Apoptosis signaling and bcl-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev. 2018;32(1):8–28. doi:10.1016/j.blre.2017.08.004
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2-family proteins and hematologic malignancies: History and future prospects. Blood. 2008;111(7):3322–3330. doi:10.1182/blood-2007-09-078162
   PubMed Web of Science ®Google Scholar
• Robinson BW, Behling KC, Gupta M, et al. Abundant anti-apoptotic bcl-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol. 2008;141(6):827–839. doi:10.1111/j.1365-2141.2008.07100.x
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-868752
   PubMed Web of Science ®Google Scholar
• Hohtari H, Kankainen M, Adnan-Awad S, et al. Targeting apoptosis pathways with bcl2 and mdm2 inhibitors in adult b-cell acute lymphoblastic leukemia. Hemasphere. 2022;6(3):e701. doi:10.1097/HS9.0000000000000701
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase ii study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117. doi:10.1158/2159-8290.CD-16-0313
   PubMed Web of Science ®Google Scholar
• Pullarkat VA, Lacayo NJ, Jabbour E, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440–1453. doi:10.1158/2159-8290.CD-20-1465
   PubMed Web of Science ®Google Scholar
• La Starza R, Cambo B, Pierini A, et al. Venetoclax and bortezomib in relapsed/refractory early t-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol. 2019;3:PO.19.00172.
   PubMedGoogle Scholar
• Zhang X, Li J, Jin J, et al. Relapsed/refractory early t-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus hag regimen. Ann Hematol. 2020;99(2):395–397. doi:10.1007/s00277-019-03902-9
   PubMed Web of Science ®Google Scholar
• Wan CL, Zou JY, Qiao M, et al. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory t-cell acute lymphoblastic leukemia: A case series. Leuk Lymphoma. 2021;62(13):3300–3303. doi:10.1080/10428194.2021.1957876
   PubMed Web of Science ®Google Scholar
• Kapoor I, Bodo J, Hill BT, et al. Targeting bcl-2 in b-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020;11(11):941. doi:10.1038/s41419-020-03144-y
   PubMed Web of Science ®Google Scholar
• Tsao T, Shi Y, Kornblau S, et al. Concomitant inhibition of DNA methyltransferase and bcl-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012;91(12):1861–1870. doi:10.1007/s00277-012-1537-8
   PubMed Web of Science ®Google Scholar
• Rahmat LT, Nguyen A, Abdulhaq H, et al. Venetoclax in combination with decitabine for relapsed t-cell acute lymphoblastic leukemia after allogeneic hematopoietic cell transplant. Case Rep Hematol. 2018;2018:6092646.
   PubMed Web of Science ®Google Scholar
• Cheung LC, Aya-Bonilla C, Cruickshank MN, et al. Preclinical efficacy of azacitidine and venetoclax for infant kmt2a-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. Leukemia. 2023;37(1):61–71. doi:10.1038/s41375-022-01746-3
   PubMed Web of Science ®Google Scholar
• Jones CL, Stevens BM, D'Alessandro A, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34(5):724–740.e4. doi:10.1016/j.ccell.2018.10.005
   PubMed Web of Science ®Google Scholar
• Othman TA, Tenold ME, Moskoff BN, et al. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. Expert Rev Hematol. 2021;14(5):407–417. doi:10.1080/17474086.2021.1938533
   PubMed Web of Science ®Google Scholar
• Sandhu KS, Dadwal S, Yang D, et al. Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2020;26(12):e322–e327. doi:10.1016/j.bbmt.2020.08.027
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Delbridge AR, Grabow S, Strasser A, et al. Thirty years of bcl-2: Translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16(2):99–109. doi:10.1038/nrc.2015.17
   PubMed Web of Science ®Google Scholar
• Um HD. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: A review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget. 2016;7(5):5193–5203. doi:10.18632/oncotarget.6405
   PubMedGoogle Scholar
• Jin S, Cojocari D, Purkal JJ, et al. 5-azacitidine induces noxa to prime aml cells for venetoclax-mediated apoptosis. Clin Cancer Res. 2020;26(13):3371–3383. doi:10.1158/1078-0432.CCR-19-1900
   PubMed Web of Science ®Google Scholar
• Klocke H, Dong ZM, O'Brien C, et al. Venetoclax and decitabine for t/myeloid mixed-phenotype acute leukemia not otherwise specified (mpal nos). Case Rep Hematol. 2020;2020:8811673.
   PubMed Web of Science ®Google Scholar
• Qin Y, Kuang P, Liu T. Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: A systematic review and meta-analysis. Clin Exp Med. 2023;23(2):219–227. doi:10.1007/s10238-021-00784-y
   PubMed Web of Science ®Google Scholar
• Aldoss I, Yang D, Pillai R, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol. 2019;94(10):E253–E255. doi:10.1002/ajh.25567
   PubMed Web of Science ®Google Scholar
• Winters AC, Maloney KW, Treece AL, et al. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatr Blood Cancer. 2020;67(10):e28398. doi:10.1002/pbc.28398
   PubMed Web of Science ®Google Scholar
• Giebel S, Czyz A, Ottmann O, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the acute leukemia working party of the european society for blood and marrow transplantation. Cancer. 2016;122(19):2941–2951. doi:10.1002/cncr.30130
   PubMed Web of Science ®Google Scholar